PX1 Research has announced the release of new batches of Retatrutide and Tirzepatide research peptides, manufactured under current Good Manufacturing Practice (cGMP) standards in USA-based facilities. Every batch is verified through high-performance liquid chromatography (HPLC) batch verification, with Certificates of Analysis confirming purity ratings of 99% or above. This development marks a significant expansion of the company's dual-incretin peptide catalog, offering researchers a reliable source for these complex molecules.
The manufacturing process adheres to cGMP standards, which govern facility conditions, equipment qualification, personnel training, and documentation practices. PX1 Research leverages over 16 years of peptide manufacturing expertise, ensuring precision in formulation and rigorous quality control. For research institutions and procurement teams, domestic cGMP manufacturing provides a traceable chain of production documentation, which is critical for maintaining data integrity in experiments that rely on consistent compound performance.
Each batch of Retatrutide and Tirzepatide undergoes a seven-stage testing protocol before shipment. HPLC batch verification serves as the analytical backbone, separating peptide compounds to quantify purity with high resolution. Beyond chromatographic purity, the testing includes checks for endotoxin contamination, amino acid sequence integrity, and accurate mass through spectrometric analysis. The result is a batch-specific Certificate of Analysis, allowing researchers to reference test results for their specific shipment rather than relying on generalized lot data. This level of documentation is considered a standard methodology in pharmaceutical-grade testing and is applied at the batch level, ensuring every shipment is individually verified.
Both compounds are central to current metabolic and endocrine research. Tirzepatide is a dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Retatrutide extends this mechanism as a triple agonist, also engaging the glucagon receptor. The structural complexity of these molecules demands high manufacturing precision, as minor deviations can alter receptor binding profiles. PX1 Research's unified manufacturing and verification framework allows research teams to source both peptides with comparable documentation, facilitating studies that compare the two or run parallel arms.
The newly released batches are available for procurement through PX1 Research's catalog, with the Retatrutide offering accessible at px1research.com and the Tirzepatide offering at px1research.com. Certificates of Analysis for current batch numbers are provided alongside each product listing. This release underscores the importance of verified, high-purity peptides in research, where compound quality directly influences experimental outcomes and reproducibility.
